Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.48 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15323520 | 0.93 | HPGD (0.52) | HPGDTAS1R3TAS1R1NT5EIMPDH2 | |
| SCHEMBL2218829 | 0.90 | HPGD (0.57) | HPGDTAS1R3TAS1R1NT5EADORA1 | |
| SCHEMBL888070 | 0.90 | HPGD (0.57) | HPGDTAS1R3TAS1R1NT5EADORA1 | |
| SCHEMBL30670293 | 0.88 | HPGD (0.55) | HPGDTAS1R3TAS1R1NT5EADORA1 | |
| SCHEMBL17438077 | 0.88 | HPGD (0.57) | HPGDTAS1R3TAS1R1NT5EADORA1 | |
| SCHEMBL15328981 | 0.87 | HPGD (0.55) | HPGDTAS1R3TAS1R1NT5EADORA1 | |
| SCHEMBL25408283 | 0.87 | HINT1 (0.56) | HPGDTAS1R3TAS1R1NT5EIMPDH2 | |
| SCHEMBL25525 | 0.87 | HPGD (0.56) | HPGDTAS1R3TAS1R1NT5ETGM2 | |
| SCHEMBL23149828 | 0.86 | NT5E (0.55) | HPGDTAS1R3TAS1R1NT5EADORA1 | |
| SCHEMBL18007488 | 0.86 | TAS1R3 (0.65) | TAS1R3TAS1R1NT5EIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600965-B2 | Modified double stranded oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12503699-B2 | Compositions and methods for silencing UGT1a1 gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12460206-B2 | PCSK9 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250333737-A1 | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250277218-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | BANK OF AMERICA, N.A. | 2025-09-04 | — | — | US | disclosed |
| US-20250270562-A1 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | BANK OF AMERICA, N.A. | 2025-08-28 | — | — | US | disclosed |
| US-20160145629-A1 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-05-26 | — | — | US | disclosed |
| US-20160122759-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160115476-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160017335-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-20160017330-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-9133461-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9127274-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150111841-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-04-23 | — | — | US | disclosed |
| US-20130317081-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2013-11-28 | — | — | US | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | EIF2AK2, DCLRE1B, DNASE1L3 | HPGD 4482/4885TAS1R3 2349/4885TAS1R1 2628/4885 |
| US-12600965-B2 | Modified double stranded oligonucleotide | NSUN2, EIF2AK2, ADAR | HPGD 4867/4885TAS1R3 1214/4885TAS1R1 989/4885 |
| US-12460206-B2 | PCSK9 iRNA compositions and methods of use thereof | PCSK9, LDLR, RNASE1 | HPGD 4490/4885TAS1R3 4136/4885TAS1R1 4220/4885 |
| US-20160017335-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PCSK9, LDLR, RNASE1 | HPGD 4490/4885TAS1R3 4136/4885TAS1R1 4220/4885 |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, APOL1, LDLR | HPGD 3563/4885TAS1R3 3348/4885TAS1R1 4529/4885 |
| US-20160122759-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ADAR, RNASEH1, NSUN2 | HPGD 3818/4885TAS1R3 2402/4885TAS1R1 2170/4885 |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PLG, PLAU, PLAUR | HPGD 3297/4885TAS1R3 3357/4885TAS1R1 3624/4885 |
| US-20250277218-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | PCSK9, PCSK7, PCSK6 | HPGD 3065/4885TAS1R3 4511/4885TAS1R1 4586/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | HPGD 3605/4885TAS1R3 1533/4885TAS1R1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.